Product Data Sheet

STING agonist-31

Target:

Cat. No.: HY-153546 CAS No.: 2719001-44-0 Molecular Formula: $C_{_{43}}H_{_{51}}N_{_{15}}O_{_6}$ Molecular Weight: 873.96

Pathway: Immunology/Inflammation

STING

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	STING agonist-31 is a STING agonist, with EC $_{50}$ values of 0.24 and 39.51 μ M for h-STING and m-STING. STING agonist-31 has antitumor efficiency $^{[1]}$.	
In Vitro	STING agonist-31 (Compound 40) activates h-STING and m-STING with EC $_{50}$ values of 0.24 and 39.51 μ M $^{[1]}$. STING agonist-31 (0-10 μ M, 24 h) activates the ISG signaling and NF- κ B signaling $^{[1]}$. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	STING agonist-31 (Compound 40) (10 mg/kg, i.v.) inhibits tumor growth in 4T1 and CT26 tumor mice model ^[1] . STING agonist-31 (1 mg/kg, i.v., rats) shows T _{1/2} : 0.697 h, AUC _{last} : 678 h•ng/mL ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Mice models bearing orthotopic transplanted breast tumor (4T1) or subcutaneous transplanted colon tumor (CT26) $^{[1]}$
	Dosage:	10 mg/kg
	Administration:	i.v., at days 1, 4, and 7
	Result:	Inhibited tumor Growth.

REFERENCES

[1]. Song Z, et al. Structure-Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists. J Med Chem. 2021 Feb 11;64(3):1649-1669.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA